XOVR ETF: The Free Anduril Backdoor, Honestly Assessed

The XOVR ETF is the rare newsletter teaser that is actually free. In Banyan Hill’s Next Elon presentation, Matt Milner hands over the four-letter ticker in the video itself, no email gate, no credit card: “you can get this four-letter ticker symbol for free, no credit card needed, no email address to fill in, no strings at all, right here in this video. The first letter is X. The second letter is O. The third letter is V. The fourth letter is R.”

XOVR is the ERShares Private-Public Crossover ETF, and its distinguishing feature is that it holds private companies inside an ordinary brokerage-tradable fund. ERShares converted it from the ENTR Entrepreneurs ETF on August 29, 2024, and publicly confirms Anduril Industries among its private holdings, alongside SpaceX and other pre-IPO names. For investors searching for a way to own a piece of Palmer Luckey’s defense company before an IPO, this is the only one-click answer on the market.

Our full Next Elon teardown covers the whole presentation. This piece assesses the fund on its own merits.

What XOVR Actually Holds

The structure matters more than the headline. Private companies make up roughly 15% of the fund, with the remainder in public equities. Anduril is a holding but not a top-10 position, so a dollar into XOVR buys you a small sliver of Anduril inside a diversified portfolio. At the time of recording, Milner put the share price around $50.

That makes XOVR two things at once: a legitimately innovative vehicle for private-market exposure, and a diluted instrument for anyone treating it as an Anduril proxy. Both descriptions are true at the same time, and the difference between them is the difference between the free ticker and the paid pitch.

The private sleeve is the part worth watching. ERShares’ crossover strategy exists because ordinary ETF rules were loosened to allow a minority allocation to private names, and the fund’s ability to hold Anduril, SpaceX, and other pre-IPO companies in a plain brokerage account is genuinely new in retail investing. Before the 2024 conversion, that access required accredited-investor status or a fund relationship most individuals could not get. The trade-off is opacity: private positions are marked by the manager rather than a live market price, so the fund’s reported NAV can lag reality in both directions. That is the deal the structure offers, and it is a fair one as long as buyers understand what they are holding.

The Pitch’s Own Caveats, Worth Repeating

To Milner’s credit, the presentation critiques its own free recommendation rather than overselling it. The key passage, quoted in full because it is unusually candid for the genre:

“XOVR isn’t exactly a pure play on Anduril… Anduril isn’t even in the fund’s top 10 holdings. In fact, private companies only make up 15% of the fund itself… what if they decide to sell their shares early? … There goes what little stake you had.”

That last point is the structural quirk most investors miss. In a crossover fund, the manager decides when private positions are sold, and the dilution and exit mechanics are not things a shareholder controls. If Anduril’s private stake were sold early or the position marked down between rounds, the shareholder has no direct say. That is a feature of the structure, not a flaw in the fund, but it belongs in any honest assessment.

Where the Paid Research Starts

After knocking down the ETF’s limitations, the presentation pivots to the thesis that “the real 10x gains, the ones I’ve been telling you about, those will likely come from those who own a stake in the secret suppliers to Anduril.” The three supplier names sit behind the report “How to 10X Your Money with the Secret Suppliers of Anduril,” part of a $299 three-month Grey Swan Investment Fraternity trial with a 30-day full refund.

Our assessment of that route is in the full Next Elon teardown, which also covers the founder story behind the whole theme.

Why Free Tickers Matter

Most promos in this family keep the “free” reveal behind the email wall and deliver a ticker that turns out to be context, not a real holding. XOVR is the exception that proves a better pattern exists: a purchasable security, confirmed by its issuer, holding the teased company. You can evaluate XOVR today in any brokerage account without buying anything from Banyan Hill.

For the broader defense-tech theme around Anduril, see our AI defense stocks coverage and the Behind the Markets Arsenal review for a second publisher’s take on defense suppliers.

The honest summary of XOVR: real fund, real Anduril exposure, honestly disclosed dilution, and a manager-controlled exit mechanic that belongs in your due diligence. As a first taste of the pre-IPO theme it is hard to beat, and as a core Anduril position it was never designed to serve.

NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.